Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

Historical failures in CNS drugs stem from treating severe, late-stage pathology. Success will come from using better biomarkers to intervene earlier and combining therapies. The speaker envisions a future of 'rational polypharmacy,' where drugs targeting different pathological drivers (e.g., excitability, inflammation) are used in concert.

Evidence indicates Parkinson's originates with gut problems and inflammation. Misfolded proteins form in the gut and slowly travel up the vagus nerve to the brain over 10 years, eventually causing motor symptoms, suggesting gut health is key to prevention.

Al Sandrock predicts Alzheimer's treatment will shift from managing symptoms to prevention. Like cholesterol, amyloid buildup will be monitored via routine blood tests, allowing for treatment to be administered early to prevent irreversible neuron loss before cognitive impairment begins.

Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Diverging from typical approaches that focus on damaged neurons, Neuvivo's drug addresses ALS as an immune system disorder. By supplying a molecule the immune system is missing, it helps regulate the system, allowing the body to recover from the attacks that cause neurodegeneration.

Senescent cells are not inactive; they are metabolically active and secrete inflammatory molecules known as SASP (Senescence-Associated Secretory Phenotype). This initially helps clear damage, but as these cells accumulate with age, the chronic inflammation they cause can worsen diseases like Alzheimer's, heart disease, and liver fibrosis.

A paradigm shift in medicine suggests that unseen, low-level inflammation is not merely a consequence of disease but a fundamental root cause. This "silent fire" is a common thread linking top killers like heart disease, cancer, diabetes, and even neurodegenerative disorders, preceding their development by years.